Company: National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)
Job title: Director Lupus Clinical Research
Director of Lupus Clinical Research and Associate Research Physician at the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) in Bethesda, Maryland, USA. Post-graduate training in Internal Medicine and Rheumatology from State University of New York at Stony Brook and completed a master’s in clinical research from Duke University. Joined the NIH intramural research program in July 2009 and with focus of research on Systemic Lupus Erythematosus. Involved in multiple clinical and translational research projects focusing on pathogenesis, outcomes and treatment of SLE. Part of the core teaching faculty for the rheumatology fellowship training program and a mentor member of the National Research Mentoring Network (NRMN). Established a regional network of local practitioners, patients and patient advocacy groups interested in advancing clinical research in SLE called DC Lupus Consortium (DCLC). Presented research at multiple regional, national and international conferences, medical grand rounds and patient summits. Authored more than 50 manuscripts and book chapters.
Tofacitinib Modulates Cardiometabolic & Immunologic Disease Markers Associated with Premature Atherosclerosis in SLE 11:00 am
JAK inhibitors can mitigate the aberrant activation of innate immune pathways in SLE Tofacitinib is not associated with severe adverse events when used in mild-moderate SLE Tofacitinib increases the number and size of high density lipoprotein particles and vascular endothelial dysfunction, associated with premature atherosclerosis in SLE Read more
day: Bonus Content